Physical urticaria: Review on classification, triggers and management with special focus on prevalence including a meta-analysis

Abstract

Our results must be viewed with circumspection because of the small number of eligible articles and heterogeneity among studies. Even so, the results suggest that PU is an important subset of CU and that physicians should be aware of this important condition in order to manage patients appropriately.

Omalizumab in Chronic Urticaria: An Italian Survey

“…The rapid response to omalizu­mab in CIndU patients was in line with the literature and during the second cycle all patients achieved a complete response [11]. In the literature, the co-occurrence of CIndU and CSU is attested from 4 to 76% [13] and is currently interpreted as a negative prognostic factor of severe urticaria [7, 14]. Current evidence highlights that (a) upon interrupting omalizumab therapy after the end of the cycles a significant number of patients re-experienced urticaria, (b) urticaria is an umbrella term that encloses several clinical entities with different pathogeneses, (c) omalizumab is an effective drug for controlling CIndU with or without CSU, and (d) aquagenic urticaria may benefit from omalizumab.…”

Chronic inducible urticaria: A systematic review of treatment options

“…We used the same search strategy as described in the methods report for the 2017 revision and update of the "EAACI/GA 2 March 2016]) with use of a trial filter (see Appendix E1 in this article's Online Repository at www.jacionline.org). 7 We ran an update search on March 13, 2017, and limited the time to 2016/2017.…”

Chronic Inducible Urticaria Part I

“…Oral anticholinergics have been tried with failure mostly. Use of pre-exercise propranolol 80 mg daily has been found efective in controlling the symptoms of CU [17]. These data have not been supported by further studies because of the fact that beta-blockers, themselves, cause allergic reactions.…”